Government-Owned Inventions; Availability for Licensing, 73337-73338 [E8-28611]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 232 / Tuesday, December 2, 2008 / Notices
Written comments and
recommendations concerning the
proposed information collection should
be sent within 30 days of this notice to
the desk officer for HRSA, either by email to OIRA submission@omb.eop.gov
or by fax to 202–395–6974. Please direct
all correspondence to the ‘‘attention of
the desk officer for HRSA.’’
Dated: November 24, 2008.
Alexandra Huttinger,
Director, Division of Policy Review and
Coordination.
[FR Doc. E8–28541 Filed 12–1–08; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
jlentini on PROD1PC65 with NOTICES
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Method for Detection of Cancer Based
on Spatial Genome Organization in the
Cell Nucleus
Description of Technology: The
successful treatment of cancer is
correlated with the early detection of
the cancerous cells. Conventional
cancer diagnosis is largely based on
qualitative morphological criteria, but
more accurate quantitative tests could
greatly increase early detection of
malignant cells. It has been observed
that the spatial arrangement of DNA in
the nucleus is altered in cancer cells in
comparison to normal cells. Therefore,
VerDate Aug<31>2005
20:52 Dec 01, 2008
Jkt 217001
it is possible to distinguish malignant
cells by mapping the position of labeled
marker genes in the nucleus.
This NIH invention provides methods
of detecting abnormal cells in a sample
using the spatial position of one or more
genes within the nucleus of a cell, as
well as a kit for detecting abnormal cells
using such methods. The invention also
provides methods of identifying gene
markers for abnormal cells using the
spatial position of one or more genes
within the nucleus of a cell.
Applications: Diagnostic for cancer
from tumor biopsies after non-invasive
techniques such as a mammogram or
PSA assay have suggested cancer.
Advantages:
• Sensitive detection of cancer.
• Very small sample (100–200 cells)
reduces the need for invasive
procedures.
• Does not require mitotic
chromosomes.
• Applicable to solid tumors and
blood cancers.
• Single cell assay allows analysis of
subpopulations from biopsy.
• Probes to all genomic regions are
available.
• Alternative or complementary to
conventional diagnostics.
• Measures metastatic potential of
cancer cells.
• Determination of tumor type.
Market:
• This novel in vitro diagnostic test
for cancer has use in oncology
laboratories of hospitals and commercial
clinical laboratories.
• In the United States, almost 1.5
million new cancer cases are expected
to be diagnosed in 2008.
Development Status: Presently in the
process of validating the assay using a
larger set of tumor samples.
Inventors: Tom Misteli and Karen
Meaburn (NCI).
Publication: KJ Meaburn and T
Misteli. Locus-specific and activityindependent gene repositioning during
early tumorigenesis. J Cell Biol. 2008 Jan
14;180(1):39–50.
Patent Status: U.S. Provisional
Application No. 61/094,318 filed 04 Sep
2008 (HHS Reference No. E–283–2008/
0-US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Whitney Hastings;
301–451–7337; hastingw@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Cell
Biology of Genomes Group, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize diagnostic methods for
detection of cancer using spatial genome
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
73337
organization. Please contact John D.
Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
A Novel, Non-Invasive and
Therapeutically Useful High
Throughput Technique To Isolate
Highly Enriched Tumor Reactive
Lymphocytes From Peripheral BloodPotential Use in Adoptive
Immunotherapy
Description of Technology: The
adoptive transfer of autologous antigen
reactive lymphocytes has been shown to
mediate significant tumor regression in
some patients with metastatic cancer.
However, the isolation of these T
lymphocytes requires invasive surgery,
which can lead to post-operative
complications and delays in initiating
adoptive immunotherapy with T cells.
This technology is directed to the use
of a novel high throughput technique to
isolate highly enriched tumor reactive
lymphocytes in a non-invasive manner
from the peripheral blood of cancer
patients for the purpose of cancer
immunotherapy. The technique utilizes
a highly sensitive PCR based screening
assay.
Applications: The isolated T
lymphocytes can be used in adoptive
immunotherapy for the treatment of
metastatic cancer.
Advantages:
• A rapid and non-invasive high
throughput method of isolating tumor
reactive T cells, which is otherwise
difficult with conventional peripheral
blood isolating techniques.
• The method is easy to use and
based on a highly sensitive PCR based
screening assay.
• The method can detect the presence
of extremely rare T cells in a bulk
population of peripheral blood cells.
Development Status: The method of
isolating tumor reactive T lymphocytes
has been established. The method was
successfully used to isolate tumor
reactive T cells from peripheral blood of
cancer patients.
Inventor: Udai S. Kammula (NCI).
Patent Status: U.S. Patent Application
No. 61/027,623 filed 11 Feb 2008 (HHS
Reference No. E–003–2008/0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Sabarni K.
Chatterjee, PhD; 301–435–5587;
chatterjeesa@mail.nih.gov
Collaborative Research Opportunity:
The National Cancer Institute, Surgery
Branch, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this high throughput T
E:\FR\FM\02DEN1.SGM
02DEN1
73338
Federal Register / Vol. 73, No. 232 / Tuesday, December 2, 2008 / Notices
cell isolation technology. Please contact
John D. Hewes, PhD at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
jlentini on PROD1PC65 with NOTICES
Ectopic Thymidylate Synthase
Accelerates the Development of
Hyperplastic Foci and Adenomas in
Pancreatic Islets
Description of Technology:
Thymidylate synthase (TS) is an E2F1regulated enzyme essential for DNA
synthesis and repair. Elevated levels of
TS protein and mRNA levels are
associated with many human cancers.
Previous research by the NIH inventors
has demonstrated that ectopic
expression of catalytically active TS is
sufficient to induce a transformed
phenotype in mammalian cells as
manifested by foci formation, anchorage
independent growth, and tumor
formation in nude mice. Overexpression
of hTS in murine islets provides a
model to study genetic alterations
associated with the progression from
normal cells to hyperplasia and
adenoma and suggests that this mouse
model may be useful for cancer
prevention and the development of
therapeutic strategies.
Applications:
• Transgenic mouse model to develop
cancer therapeutics.
• Drug screening for tumor reduction
and prevention.
Market: Cancer therapeutic
development.
Development Status: Thymidylate
synthase transgenic mice available.
Inventor: Maria Zajac-Kaye (NCI).
Patent Status: HHS Reference No.
E–088–2006/0—Research Tool. Patent
prosecution is not being pursued for this
technology.
Publications:
1. L Rahman, D Voeller, M Rahman,
S Lipkowitz, C Allegra, JC Barrett, FJ
Kaye, M Zajac-Kaye. Thymidylate
synthase as an oncogene: a novel role
for an essential DNA synthesis enzyme.
Cancer Cell. 2004 Apr; 5(4):341–351.
2. D Voeller, L Rahman, M ZajacKaye. Elevated levels of thymidylate
synthase linked to neoplastic
transformation of mammalian cells. Cell
Cycle. 2004 Aug; 3(8):1005–1007.
3. M Chen, L Rahman, D Voeller, E
Kastanos, SX Yang, L Geigenbaum, C
Allegra, FJ Kaye, P Steeg, M Zajac-Kaye.
Transgenic expression of human
thymidylate synthase accelerates the
development of hyperplasia and tumors
in the endocrine pancreas. Oncogene.
2007 Jul 19; 26(33):4817–4824.
Licensing Status: Available for
licensing.
VerDate Aug<31>2005
20:52 Dec 01, 2008
Jkt 217001
Licensing Contact: Betty B. Tong,
Ph.D.; 301–594–6565;
tongb@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Medical
Oncology Branch, is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the Thymidylate
Synthase Transgenic Animal Model.
Please contact John D. Hewes, PhD at
301–435–3121 or hewesj@mail.nih.gov
for more information.
Dated: November 24, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–28611 Filed 12–1–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Detection and Quantification of HIV
Antigen
Description of Technology: The
invention relates to a novel, costeffective method of detecting HIV
antigens, in particular HIV Gag (p24)
antigen, in human biological samples.
The method relies on using a novel
combination of a bead coated with a
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
primary high affinity monoclonal
antibody specific for p24 antigen and a
secondary antibody conjugated with a
fluorescent label that is also specific for
p24 antigen. This detection method
requires only approximately 50 µl of
sample, and is able to detect the
presence of HIV p24 antigen over a
range of concentrations from 20,000
picograms down to 0.3 picograms with
very low intrasample variability. The
upper and lower limits of the detection
method can be adjusted by altering the
components of the assay.
Applications: Detection of HIV
antigens in biological samples.
Advantages:
• Cost-effective
• Minimal amounts of sample
required
• High sensitivity and dynamic range
Development Status: In vitro data can
be provided upon request.
Market: HIV Diagnostics.
Inventors: Jean-Charles Grivel et al.
(NICHD).
Publications: Manuscript in press.
Patent Status: U.S. Provisional
Application No. 61/082,937 filed 23 Jul
2008 (HHS Reference No. E–240–2008/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Kevin W. Chang,
PhD; 301–435–5018;
changke@mail.nih.gov.
Compositions and Methods for
Inhibition of Fat-Specific Protein 27
Description of Technology: FSP27
expression is regulated by PPARg, a
gene known to play a critical role in the
development of fatty liver. Overexpression of FSP27 results in an
increase in triglyceride accumulation
and an increase in cystolic vacuoles
containing lipid droplets which are
associated with development of fatty
liver disease or hepatic steatosis. This
abnormal retention of lipids in liver
cells occurs in diabetes and alcoholism
and is correlated with decreased liver
function which can often lead to
cirrhosis and sometimes death.
Presently, there are no adequate
therapies for fatty liver disease.
This technology is directed towards
compositions and methods of inhibiting
FSP27, which include antisense
compounds, small molecule inhibitors
and antibodies that target FSP27.
Application: Potential new shRNA
based therapy for steatotic liver disease
(fatty liver).
Market: Approximately 20 to 30% of
the U.S. population has some degree of
fatty liver disease, making it the most
prevalent liver disease. Meanwhile,
cirrhosis is one of the top ten causes of
death in the U.S.
E:\FR\FM\02DEN1.SGM
02DEN1
]]>Agencies
[Federal Register Volume 73, Number 232 (Tuesday, December 2, 2008)]
[Notices]
[Pages 73337-73338]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-28611]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Method for Detection of Cancer Based on Spatial Genome Organization in
the Cell Nucleus
Description of Technology: The successful treatment of cancer is
correlated with the early detection of the cancerous cells.
Conventional cancer diagnosis is largely based on qualitative
morphological criteria, but more accurate quantitative tests could
greatly increase early detection of malignant cells. It has been
observed that the spatial arrangement of DNA in the nucleus is altered
in cancer cells in comparison to normal cells. Therefore, it is
possible to distinguish malignant cells by mapping the position of
labeled marker genes in the nucleus.
This NIH invention provides methods of detecting abnormal cells in
a sample using the spatial position of one or more genes within the
nucleus of a cell, as well as a kit for detecting abnormal cells using
such methods. The invention also provides methods of identifying gene
markers for abnormal cells using the spatial position of one or more
genes within the nucleus of a cell.
Applications: Diagnostic for cancer from tumor biopsies after non-
invasive techniques such as a mammogram or PSA assay have suggested
cancer.
Advantages:
Sensitive detection of cancer.
Very small sample (100-200 cells) reduces the need for
invasive procedures.
Does not require mitotic chromosomes.
Applicable to solid tumors and blood cancers.
Single cell assay allows analysis of subpopulations from
biopsy.
Probes to all genomic regions are available.
Alternative or complementary to conventional diagnostics.
Measures metastatic potential of cancer cells.
Determination of tumor type.
Market:
This novel in vitro diagnostic test for cancer has use in
oncology laboratories of hospitals and commercial clinical
laboratories.
In the United States, almost 1.5 million new cancer cases
are expected to be diagnosed in 2008.
Development Status: Presently in the process of validating the
assay using a larger set of tumor samples.
Inventors: Tom Misteli and Karen Meaburn (NCI).
Publication: KJ Meaburn and T Misteli. Locus-specific and activity-
independent gene repositioning during early tumorigenesis. J Cell Biol.
2008 Jan 14;180(1):39-50.
Patent Status: U.S. Provisional Application No. 61/094,318 filed 04
Sep 2008 (HHS Reference No. E-283-2008/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Whitney Hastings; 301-451-7337;
hastingw@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Cell Biology of Genomes Group, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize diagnostic methods for detection of
cancer using spatial genome organization. Please contact John D. Hewes,
Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
A Novel, Non-Invasive and Therapeutically Useful High Throughput
Technique To Isolate Highly Enriched Tumor Reactive Lymphocytes From
Peripheral Blood-Potential Use in Adoptive Immunotherapy
Description of Technology: The adoptive transfer of autologous
antigen reactive lymphocytes has been shown to mediate significant
tumor regression in some patients with metastatic cancer. However, the
isolation of these T lymphocytes requires invasive surgery, which can
lead to post-operative complications and delays in initiating adoptive
immunotherapy with T cells.
This technology is directed to the use of a novel high throughput
technique to isolate highly enriched tumor reactive lymphocytes in a
non-invasive manner from the peripheral blood of cancer patients for
the purpose of cancer immunotherapy. The technique utilizes a highly
sensitive PCR based screening assay.
Applications: The isolated T lymphocytes can be used in adoptive
immunotherapy for the treatment of metastatic cancer.
Advantages:
A rapid and non-invasive high throughput method of
isolating tumor reactive T cells, which is otherwise difficult with
conventional peripheral blood isolating techniques.
The method is easy to use and based on a highly sensitive
PCR based screening assay.
The method can detect the presence of extremely rare T
cells in a bulk population of peripheral blood cells.
Development Status: The method of isolating tumor reactive T
lymphocytes has been established. The method was successfully used to
isolate tumor reactive T cells from peripheral blood of cancer
patients.
Inventor: Udai S. Kammula (NCI).
Patent Status: U.S. Patent Application No. 61/027,623 filed 11 Feb
2008 (HHS Reference No. E-003-2008/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Sabarni K. Chatterjee, PhD; 301-435-5587;
chatterjeesa@mail.nih.gov
Collaborative Research Opportunity: The National Cancer Institute,
Surgery Branch, is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize this high throughput T
[[Page 73338]]
cell isolation technology. Please contact John D. Hewes, PhD at 301-
435-3121 or hewesj@mail.nih.gov for more information.
Ectopic Thymidylate Synthase Accelerates the Development of
Hyperplastic Foci and Adenomas in Pancreatic Islets
Description of Technology: Thymidylate synthase (TS) is an E2F1-
regulated enzyme essential for DNA synthesis and repair. Elevated
levels of TS protein and mRNA levels are associated with many human
cancers. Previous research by the NIH inventors has demonstrated that
ectopic expression of catalytically active TS is sufficient to induce a
transformed phenotype in mammalian cells as manifested by foci
formation, anchorage independent growth, and tumor formation in nude
mice. Overexpression of hTS in murine islets provides a model to study
genetic alterations associated with the progression from normal cells
to hyperplasia and adenoma and suggests that this mouse model may be
useful for cancer prevention and the development of therapeutic
strategies.
Applications:
Transgenic mouse model to develop cancer therapeutics.
Drug screening for tumor reduction and prevention.
Market: Cancer therapeutic development.
Development Status: Thymidylate synthase transgenic mice available.
Inventor: Maria Zajac-Kaye (NCI).
Patent Status: HHS Reference No. E-088-2006/0--Research Tool.
Patent prosecution is not being pursued for this technology.
Publications:
1. L Rahman, D Voeller, M Rahman, S Lipkowitz, C Allegra, JC
Barrett, FJ Kaye, M Zajac-Kaye. Thymidylate synthase as an oncogene: a
novel role for an essential DNA synthesis enzyme. Cancer Cell. 2004
Apr; 5(4):341-351.
2. D Voeller, L Rahman, M Zajac-Kaye. Elevated levels of
thymidylate synthase linked to neoplastic transformation of mammalian
cells. Cell Cycle. 2004 Aug; 3(8):1005-1007.
3. M Chen, L Rahman, D Voeller, E Kastanos, SX Yang, L Geigenbaum,
C Allegra, FJ Kaye, P Steeg, M Zajac-Kaye. Transgenic expression of
human thymidylate synthase accelerates the development of hyperplasia
and tumors in the endocrine pancreas. Oncogene. 2007 Jul 19;
26(33):4817-4824.
Licensing Status: Available for licensing.
Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565;
tongb@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Medical Oncology Branch, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize the Thymidylate Synthase Transgenic
Animal Model. Please contact John D. Hewes, PhD at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Dated: November 24, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-28611 Filed 12-1-08; 8:45 am]
BILLING CODE 4140-01-P
